Evidence map›Paper›PMID 41813800›Full record

ArticleScientific reports2026

Enhancing lung cancer classification through a double attention hybrid CNN-HiFuse approach.

Aaseegha M D, Venkataramana B

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aaseegha M DDepartment of Mathematics, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Venkataramana BDepartment of Mathematics, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India. venkataramana.b@vit.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer continues to be a predominant cause of cancer-related mortality globally. In 2022, lung cancer accounted for around 2.5 million new cases and around 1.8 million fatalities, highlighting the necessity for precise and effective computer-aided diagnostics. Timely detection is especially vital for non-small cell lung cancer (NSCLC), which constitutes roughly 80–85% of all lung cancer instances, but continues to pose difficulties in standard clinical practice. This paper presents a Double Attention Hybrid CNN-HiFuse architecture for categorizing lung cancer into three classes (normal, benign, malignant) using chest Computed Tomography (CT) images. The model is trained and evaluated on the publicly accessible IQ-OTH/NCCD dataset, which comprises 1,190 CT slices from 110 patients, using a defined preprocessing and augmentation protocol to address class imbalance. The proposed Hybrid CNN-HiFuse, which combines multi-scale feature fusion with channel and spatial attention methods, is evaluated against a bespoke CNN and transfer-learning benchmarks (VGG16, ResNet50). The model attains an overall classification accuracy of 98.12% on the stated test split, with precision, recall, and F1-score of 98.17%, 98.12%, and 98.13%, respectively, surpassing the baseline designs. The confusion matrix and ROC studies demonstrate minimal misclassification rates, especially for malignant nodules, while the attention maps emphasize clinically significant areas, hence improving interpretability. The present assessment, confined to a modest single-centre CT dataset, indicates that the Double Attention Hybrid CNN-HiFuse framework is a viable candidate for incorporation into clinical decision-support systems, potentially enhancing radiologists’ efficacy in early lung cancer detection.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsConvolutional Neural NetworksHumansTomography, X-Ray ComputedClass imbalanceComputer-aided diagnosisCT image classificationDouble attention mechanismHybrid CNN-HiFuse modelLung cancer

Identifiers

PMID41813800
PMCPMC13100117

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.